Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Children and Adolescents Aged 5 to 17 Years
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
JAMA 2024 Feb 06;331(5)408-416, LR Feldstein, A Britton, L Grant, R Wiegand, J Ruffin, TM Babu, M Briggs Hagen, JL Burgess, AJ Caban-Martinez, HY Chu, KD Ellingson, JA Englund, KT Hegmann, Z Jeddy, AS Lauring, K Lutrick, ET Martin, C Mathenge, J Meece, CM Midgley, AS Monto, G Newes-Adeyi, L Odame-Bamfo, LEW Olsho, AL Phillips, RP Rai, S Saydah, N Smith, L Steinhardt, H Tyner, M Vandermeer, M Vaughan, SK Yoon, M Gaglani, AL NalewayFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.